Skip to main content
SoftOx Solutions AS logo

SoftOx Solutions AS — Investor Relations & Filings

Ticker · SOFTX ISIN · NO0010811961 LEI · 549300AETMWJS91G4A50 OL Manufacturing
Open in API
Filings indexed 574 across all filing types
Latest filing 2020-09-24 Regulatory Filings
Country NO Norway
Listing OL SOFTX

About SoftOx Solutions AS

https://soft-ox.com/

SoftOx Solutions AS is a clinical-stage pharmaceutical company that has developed a patented, non-toxic antimicrobial technology. The technology is based on a stabilized formulation of hypochlorous acid (HOCl), an endogenous molecule used by the human immune system to combat pathogens. It is designed to be highly effective against a broad spectrum of bacteria, viruses, and fungi, and to eradicate and prevent biofilm infections. A key feature of the technology is that its mode of action does not induce antimicrobial resistance (AMR). The company's development pipeline focuses on significant health challenges, with a lead candidate, SoftOx Inhalation Solution (SIS), for treating airway infections, as well as other applications in wound care and disinfection.

Recent filings

Filing Released Lang Actions
SoftOx disinfectant solution (AntiVirTM) documents excellent skin friendliness
Regulatory Filings Classification · 90% confidence The document is a press release dated September 24, 2020, announcing the results of two clinical studies regarding the skin friendliness of SoftOx disinfectant solution (AntiVirTM) compared to alcohol disinfectant and saline. This type of announcement, detailing new scientific or product performance data, is typically classified as an Earnings Release (ER) if it accompanies financial results, or more generally as a Regulatory Filing (RNS) if it's a standalone corporate announcement that doesn't fit other specific categories like M&A, Capital Change, or Dividend. Since this is a specific, non-financial performance announcement (product safety/efficacy data) and not a formal regulatory report (like 10-K or AR), and it is not a transcript (CT) or an investor presentation (IP), the most appropriate general category for a significant corporate update that isn't explicitly defined elsewhere is Regulatory Filings (RNS). However, given the context of financial reporting databases, announcements of key product milestones or study results often fall under the general 'Regulatory Filings' or sometimes 'Earnings Release' if they are part of a quarterly update cycle. Since it is a standalone announcement of results, RNS is the best fit as a general corporate update/news release that doesn't match the other specific codes.
2020-09-24 English
Issue of new shares in connection with redemption of options
Share Issue/Capital Change Classification · 98% confidence The document explicitly discusses the 'Issue of new shares in connection with redemption of options' and states that the 'share capital increase pertaining call of options has now been registered in VPS.' This directly relates to a change in the company's capital structure involving the issuance of new shares. This aligns perfectly with the definition for Share Issue/Capital Change (SHA). The document is short, but it is the primary announcement of the capital change itself, not just an announcement of a report.
2020-09-02 English
Utstedelse av nye aksjer i forbindelse med innløsning av opsjoner
Share Issue/Capital Change Classification · 98% confidence The document text is very short (697 characters) and announces the 'Utstedelse av nye aksjer i forbindelse med innløsning av opsjoner' (Issuance of new shares in connection with the exercise of options). It explicitly states that the capital increase is now registered and the shares have been issued, detailing the new share capital and the number of new shares. This directly relates to a change in the company's share structure/capital. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate classification, as it describes the finalization of a capital change resulting from option exercise.
2020-09-02 Norwegian
Meldepliktig handel
Director's Dealing Classification · 100% confidence The document text is titled 'Meldepliktig handel' (Mandatory trading/reporting) and details share purchases made by a primary insider's related party (Yana Eganova) in SoftOx Solutions AS, including dates and prices. This directly corresponds to the definition of reporting personal share transactions by company directors and executives (insider trades). This matches the 'Director's Dealing' category (DIRS). The document is short and reports specific transactions, not announcing a larger report.
2020-08-26 Norwegian
SoftOx’ sårbehandlingsløsninger (SWTS) for behandling av alvorlige infeksjoner i sår er bevist sikker og godt tolerert i avgjørende dyrestudie – åpner for første klinisk studie på mennesker.
Regulatory Filings Classification · 90% confidence The document is a press release dated August 12, 2020, announcing positive results from a preclinical (animal) study regarding SoftOx's wound treatment solutions (SWTS). The key outcome is that the solutions were proven safe and well-tolerated, which 'opens the door for the first clinical study in humans.' This type of announcement, detailing scientific progress, safety testing results, and the next steps in clinical development, is characteristic of an announcement related to drug/medical device development or regulatory progress, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal audit report (AR). Since it is a specific announcement about a scientific/clinical development milestone that doesn't fit the other specific categories (like DIV, CAP, MANG, etc.), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard corporate announcements, or potentially 'LTR' if it were about a legal proceeding, but here it is about product development success. Given the options, RNS is the most appropriate general regulatory announcement category for this type of scientific update that isn't a formal financial report or a specific corporate action.
2020-08-12 Norwegian
SoftOx Wound Treatment Solution candidates for serious infections in wounds proven safe in pivotal animal study – opening the way for first-in-human clinical trial.
Regulatory Filings Classification · 95% confidence The document announces positive results from a pivotal animal study (GLP study in minipigs) for the SoftOx Wound Treatment Solution (SWTS) candidates, concluding they were safe and well-tolerated. This announcement paves the way for a first-in-human clinical trial. This content relates to the development and testing of a medical product, which often falls under general regulatory announcements or investor updates regarding clinical progress. It is not a formal financial report (10-K, IR, ER), a management change (MANG), or a specific legal filing. Given the nature of announcing clinical progress and safety data that supports future regulatory steps, it fits best as a general regulatory announcement or a significant operational update. Since there is no specific category for 'Clinical Trial Progress Announcement,' and it is a formal announcement of a significant operational milestone, it is classified as a Regulatory Filing (RNS) as a general announcement category, or potentially an Investor Presentation (IP) if it were a slide deck, but here it reads like a press release. Considering the options, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate category for a press release detailing clinical study outcomes that open the door for regulatory submissions (like an IND/CTA application). Document length (1757 chars) is short, but it contains the full substance of the announcement, not just a notice to download a larger report. Therefore, it is not RPA.
2020-08-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.